The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Hormone Replacement Therapy in Relation to Breast Cancer
Abstract
CONTEXT: Studies of long-term hormone replacement therapy (HRT) suggest an associated increased risk of breast cancer, but whether this association differs according to histologic type of cancer has not been extensively studied. OBJECTIVE: To determine whether the association between HRT and risk of breast cancer varies by HRT formulation and differs across histologic cancer types. DESIGN, SETTING, AND PARTICIPANTS: Nested case-control study among 705 postmenopausal women enrolled in the Group Health Cooperative of Puget Sound (GHC) who were aged 50 to 74 years and had primary invasive breast cancer diagnosed between July 1, 1990, and December 31, 1995 (cases), and 692 randomly selected aged-matched female members of GHC (controls). MAIN OUTCOME MEASURE: Incidence and type of breast cancer by duration of HRT use in the 5-year period ending 1 year before diagnosis, which was ascertained from computerized pharmacy records. RESULTS: The incidence of breast cancer, all histologic types combined, was increased by 60% to 85% in recent long-term users of HRT, whether estrogen alone or estrogen plus progestin. Longer use of HRT (odds ratio [OR], 3.07 for 57 months or more; 95% confidence interval [CI], 1.55-6.06) and current use of combination therapy (OR, 3.91; 95% CI, 2.05-7.44) were associated with increased risk of lobular breast cancer. Long-term HRT use was associated with a 50% increase in nonlobular cancer (OR, 1.52 for 57 months or more; 95% CI, 1.01-2.29). CONCLUSION: Our data add to the growing body of evidence that recent long-term use of HRT is associated with an increased risk of breast cancer and that such use may be related particularly to lobular tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322401 · Cited by 1,487 · cited 1×
“THE POSSIBLE ASSOCIATION BEtween use of estrogen replacement therapy or combined estrogen-progestin replacement therapy and the incidence of breast cancer has been assessed in numerous studies.(1-28) The Collaborative Group on Hormonal Factors in Breast Cancer pooled and reanalyzed the data from most of these (52705 w…”
MethodReproductive Factors and Breast Cancer
Kelsey, J. L., Gammon, M. D., & John, E. M. (1993) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036115 · Cited by 1,446
Menopausal Estrogen and Estrogen-Progestin Replacement Therapy and Breast Cancer Risk
Schairer, C. (2000) · JAMA · doi:10.1001/jama.283.4.485 · Cited by 1,048
Estrogens, Progestogens, Normal Breast Cell Proliferation, and Breast Cancer Risk
Pike, M. C., Spicer, D. V., Dahmoush, L., & Press, M. F. (1993) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036102 · Cited by 1,010
Physiological Action of Progesterone in Target Tissues*
Graham, J. D., & Clarke, C. L. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.4.0308 · Cited by 1,008
Increased cell division as a cause of human cancer.
Preston‐Martin, S., Pike, M. C., Ross, R. K., Jones, P. A., & Henderson, B. E. (1990) · PubMed · Cited by 896
Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin
Ross, R. K. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.4.328 · Cited by 877
The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer
Key, T. J. A., & Pike, M. C. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90173-3 · Cited by 651
Progestin regulation of cellular proliferation.
CLARKE, C. L., & SUTHERLAND, R. L. (1990) · Endocrine Reviews · doi:10.1210/edrv-11-2-266 · Cited by 650
Cited by
Chlebowski, R. T., Hendrix, S. L., Langer, R. D., Stefanick, M. L., Gass, M., Lane, D., Rodabough, R. J., Gilligan, M. A., Cyr, M. G., Thomson, C. A., et al. (2003) · JAMA · doi:10.1001/jama.289.24.3243 · Cited by 1,872
Breast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease
Travis, L. B., Hill, D. A., Dores, G. M., Gospodarowicz, M., van Leeuwen, F. E., Holowaty, E., Glimelius, B., Andersson, M., Wiklund, T., Lynch, C. F., et al. (2003) · JAMA · doi:10.1001/jama.290.4.465 · Cited by 666
Clinical characteristics of different histologic types of breast cancer
Li, C. I., Uribe, D. J., & Daling, J. R. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602787 · Cited by 598
Trends in Incidence Rates of Invasive Lobular and Ductal Breast Carcinoma
Li, C. I., Anderson, B. O., Daling, J. R., & Moe, R. E. (2003) · JAMA · doi:10.1001/jama.289.11.1421 · Cited by 577
When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly
Turnheim, K. (2003) · Experimental Gerontology · doi:10.1016/s0531-5565(03)00133-5 · Cited by 527
Metadata
- Authors
- Chen, C.-L.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2002-02-13
- Volume
- 287
- Issue
- 6
- Pages
- 734
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1996164446
- Cited by
- 360
- References
- 31
- FWCI
- 26.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hormone Replacement Therapy in Relation to Breast Cancer. https://app.cochat.ai/papers/10.1001/jama.287.6.734
- The paper
- Chen, C.-L. (2002). Hormone Replacement Therapy in Relation to Breast Cancer. JAMA. https://doi.org/10.1001/jama.287.6.734
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.